Combination Therapy Shows Promise for Treating Advanced Breast Cancer
"Memoirs of Cancer" Book Now Available   - Caring About Cancer Patients
RSS Follow

Delivered by FeedBurner


Recent Posts

PANCREAS CANCER NEWS
Cervical Cancer is an International Issue
Cancer Death Rates Declining But Disparity for African Americans Still Exist
Danstock: 4 Bands 2 Raise $ 4 Cancer Research
Is a Clinical Trial Right for You?

Most Popular Posts

Sugar considered a culprit in cancer cases
Secondary Liver Cancer
The Virus HLTV-1 and Cancer
Herbs That Can Help Cancer Patients-PERIWINKLE
Antipsychotic Drug Controls "Breakthrough" Nausea and Vomiting after Chemotherapy

Categories

African American
Anal Cancer
Bladder Cancer
Brain Cancer
Breast Cancer
Breast Cancer Awareness Month
Cancer and Fertility
CANCER AND OBESITY
Cancer and Stem Cells
Cancer Care/Self-Help
CANCER EVENTS
Cancer Facts/Statistics
Cancer Information/Updates
Cancer Loss
Cancer Memories
Cancer Prevention
cancer research
Causes of cancer
Cervical cancer
Chemotherapy
Children and cancer
Clinical Trials for Cancer
colon cancer
COLORECTAL CANCER
Exciting
Head and Neck Cancer
Health Care Disparities
Help for Cancer Patient Caregivers
JOB TRAINING
Liver Cancer
LUNG CANCER
Melanoma
Metastatic Cancer
Multicultural
Multiple Myeloma Cancer
New Cancer Info.
ovarian cancer
Pancreatic Cancer
Pancreatic Cancer Awareness Month
PROSTATE CANCER
Stomach Cancer
TRIPLE NEGATIVE BREAST CANCERS

Archives

April 2013
February 2013
January 2013
December 2012
November 2012
October 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011

powered by

Caring About Cancer Patients

Combination Therapy Shows Promise for Treating Advanced Breast Cancer

Adding the drug everolimus (Afinitor) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone. Findings from the trial, called BOLERO 2, were presented last week at the San Antonio Breast Cancer Symposium

.For women who received the combination therapy, the median progression-free survival was 7.4 months compared with 3.2 months for those who received exemestane alone, Dr. Gabriel Hortobagyi of the University of Texas M. D. Anderson Cancer Center reported at the symposium. These were the latest available data, updated from preliminary results presented at the European Multidisciplinary Cancer Congress in September and resultspublished online December 7 in the New England Journal of Medicine (NEJM).

The researchers do not yet have data on whether the combination therapy improves overall survival, but they expect to have it in late 2012. In July, the randomized phase of BOLERO 2 was stopped early after an interim analysis showed an improvement in progression-free survival. The study, which was supported by Novartis, the manufacturer of Afinitor, included many participants who had previously received multiple therapies.

Everolimus inhibits a protein called mTOR, which plays a role in a signaling pathway that promotes cell growth and proliferation. Exemestane, an aromatase inhibitor, is used to treat metastatic breast cancer.

“For postmenopausal patients with hormone receptor-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control,” Dr. Hortobagyi said in a statement. This benefit should be weighed against the side effects associated with everolimus, such as fatigue and oral mucositis, the study authors noted in the NEJM article. FOR MORE ON BREAST CANCER BUY THE BOOK "MEMOIRS OF CANCER," HERE.

1 Comment to Combination Therapy Shows Promise for Treating Advanced Breast Cancer:

Comments RSS
clinical study centre on Wednesday, May 30, 2012 6:33 AM
Micro therapeutic Research Labs (MTR) is a quality driven, full service Clinical Research Organization (CRO) that provides a broad range of clinical research services to the global pharmaceutical and biotechnology industry.
Reply to comment

Add a Comment

Your Name:
Email Address: (Required)
Website:
Comment:
Make your text bigger, bold, italic and more with HTML tags. We'll show you how.
Post Comment